Phathom Pharmaceuticals Statistics
Total Valuation
PHAT has a market cap or net worth of $654.69 million. The enterprise value is $1.08 billion.
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PHAT has 69.65 million shares outstanding. The number of shares has increased by 21.20% in one year.
| Current Share Class | 69.65M |
| Shares Outstanding | 69.65M |
| Shares Change (YoY) | +21.20% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 3.94% |
| Owned by Institutions (%) | 54.04% |
| Float | 54.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.77 |
| Forward PS | 3.44 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.38
| Current Ratio | 2.38 |
| Quick Ratio | 2.19 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.70 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -59.03% |
| Return on Invested Capital (ROIC) | -76.21% |
| Return on Capital Employed (ROCE) | -169.83% |
| Revenue Per Employee | $267,070 |
| Profits Per Employee | -$773,194 |
| Employee Count | 427 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 5.33 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.68% in the last 52 weeks. The beta is 0.45, so PHAT's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -13.68% |
| 50-Day Moving Average | 8.48 |
| 200-Day Moving Average | 7.62 |
| Relative Strength Index (RSI) | 58.65 |
| Average Volume (20 Days) | 1,017,802 |
Short Selling Information
The latest short interest is 9.69 million, so 13.91% of the outstanding shares have been sold short.
| Short Interest | 9.69M |
| Short Previous Month | 8.52M |
| Short % of Shares Out | 13.91% |
| Short % of Float | 17.67% |
| Short Ratio (days to cover) | 7.12 |
Income Statement
In the last 12 months, PHAT had revenue of $114.04 million and -$330.15 million in losses. Loss per share was -$4.72.
| Revenue | 114.04M |
| Gross Profit | 99.11M |
| Operating Income | -269.00M |
| Pretax Income | -297.11M |
| Net Income | -330.15M |
| EBITDA | -268.27M |
| EBIT | -269.00M |
| Loss Per Share | -$4.72 |
Full Income StatementBalance Sheet
The company has $149.57 million in cash and $574.50 million in debt, giving a net cash position of -$424.93 million or -$6.10 per share.
| Cash & Cash Equivalents | 149.57M |
| Total Debt | 574.50M |
| Net Cash | -424.93M |
| Net Cash Per Share | -$6.10 |
| Equity (Book Value) | -405.83M |
| Book Value Per Share | -5.79 |
| Working Capital | 127.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$274.69 million and capital expenditures -$164,000, giving a free cash flow of -$274.85 million.
| Operating Cash Flow | -274.69M |
| Capital Expenditures | -164,000 |
| Free Cash Flow | -274.85M |
| FCF Per Share | -$3.95 |
Full Cash Flow StatementMargins
Gross margin is 86.91%, with operating and profit margins of -235.88% and -289.51%.
| Gross Margin | 86.91% |
| Operating Margin | -235.88% |
| Pretax Margin | -289.51% |
| Profit Margin | -289.51% |
| EBITDA Margin | -235.24% |
| EBIT Margin | -235.88% |
| FCF Margin | n/a |
Dividends & Yields
PHAT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.20% |
| Shareholder Yield | -21.20% |
| Earnings Yield | -50.43% |
| FCF Yield | -41.98% |
Analyst Forecast
The average price target for PHAT is $16.40, which is 74.47% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.40 |
| Price Target Difference | 74.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 73.79% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
